TSFG, LLC
- SEC CIK
- 0001800513
- Latest filing
- Jul 23, 2026
EOCN holding history
Galmed Pharmaceuticals Ltd. in every 13F filed by TSFG, LLC, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
EOCN overviewAll 13F holders of EOCNFull Q2 2026 holdings
- Shares (Q2 2026)
- 17
- Value
- $0
- % of portfolio
- 0.0%
- Quarters held
- 22
- Since Q1 2021
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q2 2026 | 17 | $0 | 0.0% | 00.0% | Unchanged | Holders |
| Q1 2026 | 17 | $0 | 0.0% | 00.0% | Unchanged | Holders |
| Q4 2025 | 17 | $0 | 0.0% | 00.0% | Unchanged | Holders |
| Q3 2025 | 17 | $0 | 0.0% | 00.0% | Unchanged | Holders |
| Q2 2025 | 17 | $0 | 0.0% | 00.0% | Unchanged | Holders |
| Q1 2025 | 17 | $0 | 0.0% | 00.0% | Unchanged | Holders |
| Q4 2024 | 17 | $0 | 0.0% | 00.0% | Unchanged | Holders |
| Q3 2024 | 17 | $0 | 0.0% | −183−91.5% | Reduced | Holders |
| Q2 2024 | 200 | $0 | 0.0% | 00.0% | Unchanged | Holders |
| Q1 2024 | 200 | $0 | 0.0% | 00.0% | Unchanged | Holders |
| Q4 2023 | 200 | $0 | 0.0% | 00.0% | Unchanged | Holders |
| Q3 2023 | 200 | – | – | 00.0% | Unchanged | Holders |
| Q2 2023 | 200 | $1.00K | <0.1% | 00.0% | UnchangedConverted for a 1-for-15 split | Holders |
| Q1 2023 | 3,000 | $1.00K | <0.1% | 00.0% | Unchanged | Holders |
| Q4 2022 | 3,000 | $2.00K | <0.1% | 00.0% | Unchanged | Holders |
| Q3 2022 | 3,000 | $1.00K | <0.1% | 00.0% | Unchanged | Holders |
| Q2 2022 | 3,000 | $2.00K | <0.1% | 00.0% | Unchanged | Holders |
| Q1 2022 | 3,000 | $5.00K | <0.1% | 00.0% | Unchanged | Holders |
| Q4 2021 | 3,000 | $5.00K | <0.1% | 00.0% | Unchanged | Holders |
| Q3 2021 | 3,000 | $8.00K | <0.1% | 00.0% | Unchanged | Holders |
| Q2 2021 | 3,000 | $9.00K | <0.1% | 00.0% | Unchanged | Holders |
| Q1 2021 | 3,000 | $10.0K | <0.1% | – | – | Holders |
Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.